A pharmaceutical company is preparing to register a new medi…
A pharmaceutical company is preparing to register a new medicine simultaneously in South Africa, the European Union, and the United States. The scientific data (Modules 2–5) are complete and aligned with ICH CTD requirements. However, the regulatory team proposes submitting the same Module 1 dossier to all three authorities: South African Health Products Regulatory Authority, European Medicines Agency, and U.S. Food and Drug Administration. What is the MOST appropriate regulatory strategy?
Read DetailsA pharmaceutical company is preparing a post-approval variat…
A pharmaceutical company is preparing a post-approval variation for a medicine registered in South Africa. They notice the European Union (EU) Variations Guideline classifies changes into Type IA, IB, and II, while SAHPRA has published a Variations Addendum for local submissions. Which statement best describes the relationship between the EU Variations Guideline and the SAHPRA Variations Addendum?
Read DetailsPlease download and complete the exam file below, with your…
Please download and complete the exam file below, with your answers following each question. Upload your completed single Word document or your single scanned PDF document as the answer to this question. This question will only accept one document. If you use Excel to complete your work, you will upload it in the next Canvas question. Exam document: Exam 2 GBEC 625-211 Spring 2026-1.docx
Read Details